The Society for
Functional Precision Medicine

Our Mission

The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.

Membership

  Become a Member

The SfPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients and the treatments best suited for their cancer. This is possible through research, communication, and collaboration amongst our members and with outreach to the cancer therapy community as a whole. To further the mission, we offer our members the following exclusive benefits

  • SfPM members in good standing (dues paid through Dec. 31, ) are eligible for self nominations in our monthly seminars
  • Exclusive access to our biannual newsletter curated by our board with articles, news and insights about the world of functional precision medicine.
  • A members exclusive directory with information on research interests and home institutions to facilitate collaboration and networking
  • Facilitate trainee placements in post-doc and industry settings by recognizing shared interests and partnerships
  • Free registration for SfPM Annual Meetings and special conferences
  • Access to recordings of our virtual meetings  along with contact information of speakers to connect with
  • Many more ongoing benefits

Applications for membership may be submitted at any time during the year. We look forward to having you onboard!

  Become a Member


Virtual Monthly Seminars

Come join us for our Virtual Monthly Seminar which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series is must attend for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.

Next Seminar |
November 10, 2021.

https://dfci.zoom.us

Meeting ID: 936 9981 1786
Password: 351904

 Learn More   Register

Featured Speakers

Philipp Staber, MD PhD
Philipp Staber, MD PhD
Medical University of Vienna

“Functional Precision Medicine for Patients with Hematologic Malignancies”



Recent News

Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models
October 6, 2021
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models

Researchers at MIT and Dana-Farber Cancer Institute have developed a high-throughput assay that detects subtle changes in the mass of individual drug-treated cancer cells as a surrogate biomarker for patient treatment response. Their findings suggest cell mass is a promising functional biomarker for cancers and drugs that lack genomic biomarkers.

Learn More


Precision Oncology: Beyond Biomarkers
October 3, 2021
Precision Oncology: Beyond Biomarkers

We would like to invite you to a webinar co-hosted by Oncology Convention Expo, Precision Oncology: Beyond Biomarkers on 5th October at 14:00 (BST).

Learn More


Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening
JUNE 23, 2021
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening

Sanford M. Simon and his group tested over 5,000 compounds, either already approved for other clinical uses or in clinical trials, to see whether any of the compounds could be repurposed to treat fibrolamellar. The team used PDX models to uncover a few classes of therapeutics that eliminate fibrolamellar tumor cells grown in mice.

Learn More


2021 VIRTUAL Functional Precision Medicine in Blood Cancer
JUNE 16, 2021
2021 VIRTUAL Functional Precision Medicine in Blood Cancer

The 2021 Functional Precision Medicine in Blood Cancer Symposium which took place virtually on March 25-26th, 2021 was very interesting and well attended. If you were not able to make it please take a moment to watch the recording by clicking on the "Learn More" button below.

Learn More


SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian Cancer
APRIL 13, 2021
SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS® Test in Ovarian Cancer

SEATTLE, April 13, 2021 -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived live tumor specimens employing its CLIA certified PARIS® Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS® Test (abstract number 534) at the American Association for Cancer Research annual meeting, taking place virtually from April 10-15, 2021.

Learn More


ALL NEWS